Thanks for choosing mmm-online.com Sign up for your FREE account now and join the thousands of other healthcare marketing professionals who rely on us for all the latest industry news and innovative ideas for direct and digital strategy. Simply fill out the fields below.

Keep me logged in Forgot your password?

Please wait...

Please wait...

 Pipeline

Business Briefs: Merck and Forest Labs

May 23, 2013

Merck's proposed insomnia drug scores a thumbs-up from an FDA advisory panel, and long-time Forest Labs CEO Howard Solomon announces his coming retirement.
 

J&J's Janssen looks to the margins with hep C agent

May 14, 2013

J&J scored an unexpected "priority review status" for its HCV agent simeprivir, whose initial approval is expected to be with interferon.
 

Data show Gilead's sofosbuvir has 'clean' safety profile

April 24, 2013

Phase III findings on sofosbuvir, released in a medical journal, suggest no cause for concern from a safety perspective.
 

Pfizer pipeline breast cancer drug gets fast tracked

April 11, 2013

FDA is accelerating review of Pfizer's experimental breast cancer drug palbociclib, which analysts say already has a fan base among KOLs.
 

Oncology lifts Roche's Q1, Lucentis finds new fans

April 11, 2013

Roche's oncology trifecta of Herceptin, Avastin and mabThera/Rituxan buoyed quarterly sales. Devices and diagnostics sales were solid, if less impressive.
 

More pink slips at AstraZeneca

March 21, 2013

Days after announcing a sharp downsizing, the patent expiry-plagued company said it will eliminate an additional 2,300 jobs, raising the tally of cuts to more than 5,000 through 2016.
 

Business briefs: Gilead, Shire, The Medicines Co., HHS

February 04, 2013

HHS wants input for its TXT4Tots childhood advice program, Gilead releases some Hep. C clinical trial data, and Shire settles with the DOJ over disputed marketing practices.
 

Company news: Boehringer Ingelheim, GlaxoSmithKline

January 14, 2013

Boehringer, Horizon Discovery sign collaboration agreement; GSK files for HGS diabetes therapy
 

Trial designed with crowd input gets FDA signoff

December 28, 2012

Transparency Life Sciences is tapping the wisdom of the crowd, with FDA's imprimatur, in an effort to make the drug development process more sustainable.
 

Study: Pharma getting more drugs approved, but less money for them

December 17, 2012

Researchers said the industry closed 2012 with a mixed bag of results. The upside: more approvals than last year. The downside: projected sales for these new drugs is less.
 

Lilly takes solanezumab for another spin

December 13, 2012

The drug maker will roll out another Phase III trial.
 

Gilead expands its oncology pipeline

December 12, 2012

Gilead's $510 million deal to buy YM Biosciences will bring an experimental bone marrow therapy under its roof.
 

Company news: Janssen, Pfizer, BMS and Boehringer Ingelheim

December 11, 2012

Janssen's prostate cancer pill Zytgia got an OK for use in an earlier line of therapy, and drugmakers Pfizer, Bristol-Myers Squibb and Boehringer Ingelheim released new data on blood thinners Eliquis and Pradaxa.
 

Takeda's buying spree continues with CNS splurge

November 06, 2012

Takeda is plunking down $140 million for Envoy Therapeutics and its CNS tech
 

Company news: Eli Lilly

October 23, 2012

Eli Lilly said its Phase III AWARD trials for its weekly dulaglutide GLP-1 drug, in testing for type 2 diabetes, met primary efficacy endpoints and demonstrated superiority for HbA1c lowering over exenatide and metformin.
 

"I just want to say one word to you: biologics"

October 23, 2012

Biologics are making their way through the FDA approval process at a much faster clip than small molecule drugs these days, and just might unclog pharmas' slow-moving pipelines
 

BMS, Abbott HCV pill data suggest competition for Gilead

October 16, 2012

Abbott and BMS peeled back the curtain on some impressive clinical trial results, suggesting that Gilead may have some competition in the sprint for an all-oral anti-HCV treatment.
 

Boehringer Ingelheim prepares to launch oncology franchise

October 02, 2012

Boehringer Ingelheim has long been associated with treatments for stroke prevention, COPD and HIV/AIDS, but not cancer. That's about to change, if a cornucopia of 13 abstracts presented at the European Society for Medical Oncology (ESMO) is any evidence.
 

Eli Lilly to write off schizophrenia drug

August 29, 2012

Results of a recently completed futility analysis prompted the company to stop development of its experimental drug mGLU2/3.
 

Lilly Alzheimer drug fails to hit trial goals

August 24, 2012

The company said its experimental Alzheimer's drug Solanezumab's Phase III trial was a bust—the drug failed to meet either of the Phase III targets among patients with mild to moderate Alzheimer's disease.
 

Failures halt Phase III trials of Alzheimer's drug

August 07, 2012

Phase III studies of bapineuzumab were stopped, creating few ripples in earnings outlooks, but Phase II studies of a subcutaneous form are ongoing.
 

BMS slams brakes on hepatitis C trial

August 02, 2012

A 111-word press release has touched off a swirl of doubts about Bristol-Myers Squibb's standing in the race to develop an all-oral hepatitis C regimen.
 

Lilly Q2 sales fall 10%, expenses will be trimmed

July 25, 2012

Eli Lilly's future plans include trimming not just R&D, but selling, general and administrative (SG&A) expenses as a way to increase margins.
 

Alzheimer's drug flunks in 1 of 2 populations, Pfizer says

July 24, 2012

A closely watched Alzheimer's compound being co-developed by Pfizer failed to show efficacy in one of several Phase III trials.
 

Past the patent cliff, pharmas are set for rebound in NMEs, says IMS

July 12, 2012

Industry pipelines might not be brimful of blockbusters, but after years of meager output, biopharma firms are poised to tap a cornucopia of innovative treatments as thirty-something New Molecular Entities launch each year through 2016.
 

Eliquis held up again by FDA, launch delayed at least six months

June 25, 2012

The FDA is missing another approval deadline for Eliquis, the blood thinner being developed by Bristol-Myers Squibb and Pfizer.
 

Lundbeck, building "European commercial model of the future," lays off 600

June 14, 2012

The company said in a statement that proposed layoffs will help the drugmaker weather uncertainty on pricing and reimbursement in Europe.
 

Copaxone sales likely to top out this year, Teva exec says

June 07, 2012

Sales of Teva's MS blockbuster Copaxone are likely to peak this year before giving way as more therapeutic options become available, a Teva exec says.
 

Post ASCO, talk turns to prepping BMS therapy for launch

June 06, 2012

As the big cancer meeting wound down, talk turned to the best way to prepare Bristol-Myers Squibb's anti-PD-1 antibody, a potential blockbuster, for launch.
 

BMS may have another Avastin in its oncology pipeline, analyst says

May 31, 2012

An analyst calls this Bristol-Myers Squibb agent potentially "the most exciting clinical and commercial opportunity in oncology since Avastin," plus more data reveals in the run-up to the year's most important oncology meeting.
 
  

Web Exclusive

Angelina Jolie's fearless but flawed message

Paul Oestreicher, Ph.D. May 17, 2013

Angelina Jolie's story raises important questions about education, outreach and access—but her nod to holistic treatments is less helpful
 

Podcasts

How to engage even the busiest physicians

March 04, 2013

Sponsored by TRUE Health + Wellness. The increasingly demanding schedules of healthcare professionals continue to narrow the window of opportunity for pharma sales teams, and, as a result, marketers are focusing more on non-personal promotion. However, there's a lot more to it than simply bombarding physicians with brand messages, as Anne Stroup, Managing Director at TRUE Health + Wellness, explains to MM&M's James Chase in this special podcast presentation.
 

2013 Hall of Fame Inductees

An entertaining look at the extraordinary lives and careers of the Medical Advertising Hall of Fame's 2013 inductees: Peter Frishauf, Dorothy Philips and David Labson. Clips produced by JUICE Pharma. 

Slideshows

MAHF 2013: Honors Class

A gallery of images from the 2013 Medical Advertising Hall of Fame induction dinner
 
Popular Topics
Acquisition Adherence Advertising Allergy Anaphylaxis Anti-infective App Approval Centers For Disease Control COPD Diabetes DTC Elan FDA Generic Generic Drugs Lymphoma Marketing & Communications Mobile Oncology Patient Advocacy Pipeline Regulatory Research & Development Roche